Skip to main content
PLOS One logoLink to PLOS One
. 2023 Feb 3;18(2):e0280805. doi: 10.1371/journal.pone.0280805

Developing a taxonomy to describe offspring outcomes in studies involving pregnant mammals’ exposure to non-tobacco nicotine: A systematic scoping review

Lucy Phillips 1,*, Ross Thomson 1, Tom Coleman-Haynes 1, Sue Cooper 1, Felix Naughton 2, Lisa Mcdaid 2, Joanne Emery 2, Tim Coleman 1
Editor: Saeed Ahmed3
PMCID: PMC9897539  PMID: 36735735

Abstract

Introduction

Many countries recommend Nicotine Replacement Therapy (NRT) for smoking cessation in pregnancy. Preclinical studies of nicotine exposure to pregnant mammals could indicate how nicotine may adversely affect the developing fetus. As a first step towards summarising this literature, we undertook a systematic scoping review to determine the number and nature of offspring outcomes studied.

Methods

We searched MEDLINE and EMBASE databases for papers reporting empirical data on offspring outcomes following nicotine exposure to pregnant non-human mammals. We excluded studies that investigated exposure to only smoking, e-cigarettes, nicotine vaccines, or studies with no ‘nicotine only’ group. We developed a draft taxonomy and using this, described and quantified outcomes reported.

Results

We identified 476 studies, which reported 729 offspring outcomes. The draft taxonomy classified outcomes as being measured in i) whole animals, ii) body systems and iii) ‘other’. Body system outcomes were further categorised as being functional changes, or changes at macroscopic or cellular levels. The most frequently used outcomes were those detecting changes in the brain (n = 265), physical parameters measured in whole animals (n = 122) and any respiratory system changes (n = 97).

Conclusions

This scoping review quantifies the nature and frequency of outcomes used in preclinical studies investigating the potential impacts of nicotine administration in pregnancy on offspring. Systematic reviews of studies investigating outcomes involving animal brains, respiratory system, or ‘whole animal’ outcomes may have greatest potential for further advancing knowledge regarding impacts of gestational nicotine exposure on offspring.

Protocol and registration

Protocol for this review can be found on Open Science Framework (https://osf.io/ptmzc/).

Introduction

Smoking in pregnancy causes much morbidity and mortality [1–3]. A systematic review of randomised control trials (RCTs) shows that stopping smoking in pregnancy improves birth outcomes [4]. Many countries, including the UK, recommend nicotine replacement therapy (NRT) for smoking cessation during pregnancy [5, 6] and 11% of UK pregnant smokers receive NRT prescriptions [7]. Although NRT provides nicotine without other toxic elements present in tobacco smoke, the ability for nicotine to cross the placenta and concentrate in fetal blood and amniotic fluid [8] leads to concerns that nicotine within NRT may cause fetal harm [9].

Preclinical literature could inform us of potential harms that might be due to nicotine, and many preclinical studies have investigated relationships between nicotine administered to pregnant animals and adverse outcomes [10]. However, there is no agreed core outcome set for measuring potential offspring harm from nicotine and there appears to be great diversity in outcomes used. For many preclinical study outcomes, there is no direct evidence that these are indicative of harm to humans; hence, such outcomes are probably best considered theoretically indicative of harm to infants born to pregnant women who use NRT. For example, in one study fetal brain stem injury was observed in rat offspring after gestational nicotine administration in maternal drinking water, and it was extrapolated that maternal smoking in pregnancy may cause similar issues, potentially leading to sudden infant death syndrome [11]. Other preclinical study issues which make finding’s relevance to humans difficult to ascertain include outcomes measured ‘in vitro’, in isolated parts of animals or in species which have little in common with humans [12].

Systematic reviews involve collating all studies relevant to research questions together, and through evidence synthesis can comprehensively answer important research questions[13]. For example, a recent systematic review of studies investigating NRT use by pregnant women found no evidence that NRT use during pregnancy causes fetal harm [14]. However, despite a thorough search, we have been unable to find any systematic reviews of preclinical studies investigating the impacts of nicotine exposure in pregnancy on mammalian offspring outcomes. We found a 20-year old review, but within this, search strategies were not described, so it was impossible to determine how comprehensive this was [10]. Other reviews have been narrative with selective choices of included literature [8, 15–18], and this lack of systematic preclinical literature synthesis has resulted in calls for rigorous, regularly-updated systematic reviews of preclinical studies to focus research efforts [19].

Scoping reviews allow rapid identification of unanswered research questions, and may indicate both the feasibility and potential utility of conducting full systematic reviews [20]. We have conducted a systematic scoping review of preclinical studies investigating potentially adverse impacts of gestational nicotine administration on offspring outcomes. We identify, quantify and categorise the full range of offspring outcomes measured in studies involved, and then use the taxonomy developed to hypothesise about the utility of preclinical literature for identifying potential adverse effects of nicotine on human offspring following administration of NRT in pregnancy.

Methods

We adapted the framework for conducting scoping reviews described by Arskey and O’Malley [20]. This involved: posing a research question; identifying potentially relevant studies; selecting those appropriate for inclusion; extracting and charting relevant data; and then collating, summarizing and reporting findings. We used established methods [21] to comprehensively search for preclinical studies in which non-tobacco nicotine has been administered to mammals in pregnancy, and we identified those which reported fetal or offspring outcomes.

Search strategy (identifying relevant studies)

We developed a draft MEDLINE search strategy using keywords relevant to the research question and tailored terms to make the search results more specific. We then tested the draft search strategy in MEDLINE to confirm it could find three pre-identified relevant papers, before this was finalised and adapted to run in both MEDLINE and Embase. In MEDLINE, we used the option to search for non-human studies only. However, as this option was not available for EMBASE, we applied a search filter which had been specially developed to identify all animal studies [22]. No past date restrictions were applied to either search, and these were conducted by 21st September 2022. A full list of final search terms used in study searches is outlined in S1 File.

We downloaded all identified citations into Endnote, removed duplicates and, where only titles were present, sought abstracts where possible. We then exported all citations into Covidence [23] online systematic review software, which facilitated management of the screening process. The search strategy captured journal articles in any language that reported empirical data on fetal or offspring outcomes following the administration of non-tobacco nicotine to pregnant animals. Due to the broad nature of the animal/non-human filters applied, some non-mammalian animal studies were present in search results. These were excluded during the initial title screening. Foreign language titles and abstracts were translated; studies with a title but no abstract were included if a relevant outcome was clearly stated. We decided on inclusion or exclusion using study titles and abstracts only. Although there is evidence that research papers can show inconsistencies between their abstract and full text [24], this is rarely an issue for identifying outcomes or the population of investigation.

Screening strategy (Study selection)

Initially, LP screened citations (i.e. titles +/- abstracts) and those that were obviously not relevant to the review were excluded. Next, using pre-determined inclusion and exclusion criteria, three reviewers (LP, RT and TC) each piloted study selection procedures on 100 citation records. Individual assessors noted uncertainties and discussed these with the other two researchers. Following resolution of issues arising from the pilot screening, and based on increasing familiarity with the literature, inclusion and exclusion criteria for the scoping review were finalised (Table 1). LP and RT then applied the inclusion and exclusion criteria to all the citations. Citations were grouped into those for inclusion, exclusion or where a decision could not be made. Next, all reviewers (LP, RT & TC) discussed citations where there was uncertainty about whether to include or exclude them.

Table 1. Inclusion and exclusion criteria.

Inclusion Criteria Exclusion Criteria
 • Published journal papers (not conference abstracts or reviews)
 • Papers reporting empirical data on fetal or offspring outcomes following nicotine exposure to pregnant mammals
 • Papers in any language (foreign language abstracts will be translated)
 • Studies that do not include pregnant mammals or fetal/offspring nicotine exposure during gestation (e.g in vitro studies)
 • Studies which investigate exposure to only smoking, e-cigarettes, nicotine vaccines, studies with no ‘nicotine only’ comparison group
 • Studies that include nicotine exposure to offspring in the postpartum (e.g via lactation) prior to outcome measurement.

Data extraction (charting the data)

A list of citations with an abstract were divided between two researchers (LP & TCH) who independently extracted the following: author name, publication date, animal species used and all reported outcomes (no information on nicotine exposure e.g. amount, duration or administration was extracted). For citations with no abstract, researchers extracted any outcome data that was mentioned in the title. If the title did not state a clear outcome, and no abstract was available, the citation record was excluded from the scoping review. A spreadsheet listing all outcomes extracted from abstracts and other information outlined above was compiled. As some papers used technical, discipline-specific language, where necessary, we included in the spreadsheet a lay translation of the outcomes that would assist in the draft taxonomy development. Once all outcomes had been extracted, a third researcher (RT) conducted an audit of 10% of the data extraction and lay translations to ensure consistency between researchers. Many citation records reported more than one outcome so the denominator for findings is the number of reported outcomes rather than the number of citation records.

Taxonomy development (Collating, summarizing and reporting the results)

We adopted an iterative approach to developing an outcomes taxonomy and initially grouped outcomes as either physical (e.g. weight, litter size, survival) or relating to specific body systems (e.g. brain, cardiovascular or respiratory systems). After reflecting, we judged some ‘body system’ categories too broad to be sufficiently informative and so divided these further to better describe the diversity of reported outcomes. Other categories judged to be too narrow were merged; for example, we created an overarching ‘Nervous System’ category by combining the categories for outcomes relating to the Central, Autonomic and Peripheral Nervous Systems. We also added an ‘other’ category for any outcomes that did not fit into either the ‘physical’ or ‘body system’ categories (for example, blood gasses), and this category also included any outcome parameters that were unclear. We proposed and revised category descriptors to try to make these as consistent as possible with other preclinical literature. For example, a draft descriptor ‘psychological outcomes’ was thought too ‘human’ and replaced with the descriptor ‘brain function’, which encompassed all cognitive or behavioural outcomes.

Results

Searches produced 6354 citation records, 1798 of which were duplicates. Following title and abstract screening of the remaining 4556 records, 476 records were assessed as relevant for inclusion in the scoping review (Fig 1). We were unable to obtain abstracts for seven of the 476 citation records, meaning outcomes for these citations were determined by the title alone.

Fig 1. PRISMA diagram.

Fig 1

Prisma diagram of citation selection process.

We identified 729 fetal and offspring outcomes within the 476 abstracts or titles. The majority of papers (440) reported outcomes relating to rodents, while 16 related to sheep, 14 to primates and 3 to rabbits. The draft taxonomy for categorising outcomes contains three classification groups: outcomes measured in i) complete animals, ii) body systems and, iii) ‘other’ (see Table 2).

Table 2. Draft taxonomy for categorising outcomes in preclinical literature.

Type of Outcome Outcome Subcategory 2nd Level subcategory 2nd Level Subcategory totals Subcategory Total Outcome Total
Whole animal Litter Size - - 14 122
Survival - - 21
Weight & Length - - 87
Body System Brain Cellular (hormones, DNA, chemical changes) 174 265 593
Macroscopic development 20
Function 73
Cardiovascular Cellular (hormones, DNA, chemical changes) 26 65
Macroscopic development 8
Function 31
Eyes Cellular (hormones, DNA, chemical changes) 2 4
Macroscopic development 2
Function -
Gastrointestinal system (liver, pancreas, etc.) Cellular (hormones, DNA, chemical changes) 17 20
Macroscopic development 2
Function 1
Immune system/ immune function Cellular (hormones, DNA, chemical changes) 12 15
Macroscopic development 1
Function 2
Musculoskeletal, skin & dental Cellular (hormones, DNA, chemical changes) 17 36
Macroscopic development 16
Function 3
Nervous System (CNS, ANS, PNS, etc.) Cellular (hormones, DNA, chemical changes) 14 21
Macroscopic development -
Function 7
Neuroendocrine & endocrine System Cellular (hormones, DNA, chemical changes) 28 32
Macroscopic development 1
Function 3
Renal Cellular (hormones, DNA, chemical changes) 13 18
Macroscopic development 4
Function 1
Reproductive system Cellular (hormones, DNA, chemical changes) 11 18
Macroscopic development 2
Function 5
Respiratory Cellular (hormones, DNA, chemical changes) 45 97
Macroscopic development 14
Function 38
Other Fetal Blood Gases - - 7 14
Intrauterine Development/ Developmental Parameters - - 7

1. Outcomes measured in complete animals

This comprised any outcomes measured in whole animals, such as litter size, survival, weight or length. Measures were taken either at birth or soon afterwards, and animals were alive at the time of measurement or killed immediately beforehand. In this category, 122 outcomes were distributed across 91 studies; most were weight or length (87/122).

2. Outcomes measured in body systems

This comprised outcomes that could be measured in complete animals but were more relevant to a physiological body system (e.g. cardiovascular, neurological or renal systems). Within each body system, further subcategories defined outcomes as cellular-level (e.g. hormones, DNA or chemical changes), macroscopic (i.e. directly observable without microscopic-level identification), or functional (affecting a body system, e.g. lung function measures). Of 593 outcomes, 45% (265/593) related to the brain, 16% (97/593) to respiratory, 11% (65/593) to cardiovascular, 6% (36/593) to musculoskeletal, skin and dental, and 5% (32/593) to neuroendocrine or endocrine systems. Outcomes relating to other body systems had 21 or fewer occurrences. Across all body systems, 359 outcomes were cellular-level, 70 were macroscopic and 164 related to body system function.

3. Other outcomes

This encompassed any outcomes that could not be classified into another category. For example, fetal arterial blood gas concentrations were a reported outcome in some studies, but these can occur due to disturbances in a number of body systems so categorisation is difficult. There were 14 outcomes that fell into this category.

Discussion

We have provided a thorough, quantitative description of outcomes used in preclinical studies investigating mammalian prenatal nicotine exposure. We identified 729 different fetal or offspring outcomes reported from 476 studies. The most frequently reported outcomes measured cellular-level brain changes; respiratory system outcomes measuring either cellular, macroscopic or functional changes, and physical outcomes measured in whole animals, such as birth weight and litter size.

Many studies reported multiple outcomes and, as we only extracted data from titles and abstracts; some outcomes reported only in manuscripts’ full texts may have been missed. However, authors usually include the most important study outcomes in abstracts, so we should have identified those outcomes which researchers most strongly believed to be related to maternal nicotine administration. Also, as authors are likely to be biased towards including statistically significant findings in abstracts, we have probably also identified most outcomes for which statistical associations with nicotine administration were demonstrated. If we had retrieved and extracted information from manuscripts’ text, we may have found extra methodological details to prompt either exclusion from or inclusion in the review. For example, some studies might have involved nicotine administration in both pregnancy and the weaning period, without study abstracts mentioning this. Hence, some included studies may have assessed impacts other than those of nicotine administration in pregnancy. It is unclear how much these factors might have affected the number and breadth of outcomes identified, but there is no reason to suspect effects would be substantial.

A strength of this work is its novelty. It is the first to offer a systematic and comprehensive overview of principal offspring outcomes in animal studies investigating the impacts of nicotine in pregnancy, and the draft taxonomy is the first attempt to categorise these. Another study strength lies with its rigour. We followed established methods for conducting scoping reviews and carefully developed search strategies for identifying relevant work. This included, for one of the bibliographic databases searched, applying a filter designed to find all preclinical studies. Hence, we believe that we will have missed few relevant papers. Similarly, we used a robust, team-orientated approach to extract data; two researchers independently conducted this with arbitration from a third, where necessary. Consequently, we believe that most outcomes have been identified from citations and that these will have been categorised consistently. To ensure that the draft taxonomy was appropriately descriptive, we adopted an iterative developmental approach, revising categories and descriptors to help the final version have the greatest possible utility. However, this draft taxonomy can be revised if necessary.

This work helps move the literature beyond narrative reviews [15–19]. Although the manuscript makes no quality assessments, by demonstrating which outcomes are most regularly reported, it highlights where further investigation might be most fruitful. Detailed systematic reviews would most likely provide useful information if these answered focussed questions about impacts on the brain, respiratory system or on whole animals’ physical characteristics. Such reviews could investigate the effects of varying nicotine doses and administration regimens on the same outcomes across all preclinical studies, and by including robust evaluation included studies’ methodological quality, would enable effective assessment of their findings’ validity. Such reviews would very likely help us better understand any relationships between gestational nicotine exposures and offspring harm in preclinical studies.

Whilst a systematic approach to synthesising the preclinical literature could indicate ‘signals’ of potential harms from nicotine, the question of how findings relate to humans and in particular, the impacts of NRT used in pregnancy for smoking cessation remain difficult to answer. Whether or not nicotine administered in pregnancy is harmful to human infants can only be fully answered by studies conducted in women.

Conclusions

We provide an overview of preclinical, mammalian study outcomes used to investigate impacts on offspring from prenatal nicotine exposure, and a draft taxonomy that categorises outcomes in relation to offspring’s development, affected body systems and their functions. This highlights those areas where most preclinical research has focused, and therefore could benefit most from full systematic reviews to fully understand any relationships between gestational nicotine administration and offspring harms.

Supporting information

S1 File. Search term for database searches.

Search strategy used to search MEDLINE and Embase.

(PDF)

S2 File. Included citations dataset.

Information for citations included in the systematic scoping review.

(PDF)

S3 File. Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist.

(PDF)

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This project was funded through a National Institute for Health Research (NIHR) Programme Grants for Applied Research (Programme number RP‐PG‐0615‐20003). Tim Coleman is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this manuscript are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

References

  • 1.Smoking and the young. A report of a working party of the Royal College of Physicians. London: RCP; 1992. [Google Scholar]
  • 2.Batstra L, Hadders-Algra M, Neeleman J. Effect of antenatal exposure to maternal smoking on behavioural problems and academic achievement in childhood: prospective evidence from a Dutch birth cohort. Early Human Development. 2003;75(1–2):21–33. doi: 10.1016/j.earlhumdev.2003.09.001 [DOI] [PubMed] [Google Scholar]
  • 3.Thapar A, Fowler T, Rice F, Scourfield J, van den BM, Thomas H, et al. Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. AmJ Psychiatry. 2003;160(11):1985–9. doi: 10.1176/appi.ajp.160.11.1985 [DOI] [PubMed] [Google Scholar]
  • 4.Chamberlain C, O’Mara‐Eves A, Porter J, Coleman T, Perlen SM, Thomas J, et al. Psychosocial interventions for supporting women to stop smoking in pregnancy. Cochrane Database of Systematic Reviews. 2017(2). doi: 10.1002/14651858.CD001055.pub5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.National Institute for Health and Clinical Excellence. Quitting smoking in pregnancy and following childbirth. NICE Public Health Guidance 26. London; 2010. Report No.: PH26.
  • 6.Bar‐Zeev Y, Lim LL, Bonevski B, Gruppetta M, Gould GS. Nicotine replacement therapy for smoking cessation during pregnancy. Medical Journal of Australia. 2018;208(1):46–51. doi: 10.5694/mja17.00446 [DOI] [PubMed] [Google Scholar]
  • 7.Dhalwani NN, Szatkowski L, Coleman T, Fiaschi L, Tata LJ. Prescribing of nicotine replacement therapy in and around pregnancy: a population-based study using primary care data. Br J Gen Pract. 2014;64(626):e554–60. doi: 10.3399/bjgp14X681361 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Bruin JE, Gerstein HC, Holloway AC. Long-Term Consequences of Fetal and Neonatal Nicotine Exposure: A Critical Review. Toxicological Sciences. 2010;116(2):364–74. doi: 10.1093/toxsci/kfq103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Bowker K, Campbell KA, Coleman T, Lewis S, Naughton F, Cooper S. Understanding pregnant smokers’ adherence to nicotine replacement therapy during a quit attempt: a qualitative study. Nicotine & Tobacco Research. 2016;18(5):906–12. doi: 10.1093/ntr/ntv205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Dempsey DA, Benowitz NL. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Safety. 2001;24(4):277–322. doi: 10.2165/00002018-200124040-00005 [DOI] [PubMed] [Google Scholar]
  • 11.Krous HF, Campbell GA, Fowler MW, Catron AC, Farber JP. Maternal nicotine administration and fetal brain stem damage: a rat model with implications for sudden infant death syndrome. Am J Obstet Gynecol. 1981;140(7):743–6. doi: 10.1016/0002-9378(81)90733-x [DOI] [PubMed] [Google Scholar]
  • 12.Joschko MA, Dreosti I. E., & Tulsi R. S. The teratogenic effects of nicotine in vitro in rats: a light and electron microscope study. Neurotoxicology and teratology. 1991;13(3):307- doi: 10.1016/0892-0362(91)90076-9 [DOI] [PubMed] [Google Scholar]
  • 13.Green S. Systematic reviews and meta-analysis. Singapore medical journal. 2005;46(6):270–4. [PubMed] [Google Scholar]
  • 14.Taylor L, Claire R, Campbell K, Coleman-Haynes T, Leonardi-Bee J, Chamberlain C, et al. Fetal safety of nicotine replacement therapy in pregnancy: systematic review and meta-analysis. Addiction. 2021;116(2):239–77. doi: 10.1111/add.15185 [DOI] [PubMed] [Google Scholar]
  • 15.Wong MK, Barra NG, Alfaidy N, Hardy DB, Holloway AC. Prenatal nicotine exposure and postnatal health outcomes. Reproduction. 2015;150(6):185–93. [DOI] [PubMed] [Google Scholar]
  • 16.Ernst M, Moolchan ET, Robinson ML. Behavioral and neural consequences of prenatal exposure to nicotine. Journal of the American Academy of Child & Adolescent Psychiatry. 2001;40(6):630–41. doi: 10.1097/00004583-200106000-00007 [DOI] [PubMed] [Google Scholar]
  • 17.Tiesler CT, Heinrich J. Prenatal nicotine exposure and child behavioural problems. Eur Child Adolesc Psychiatry. 2014;23(10):913–29. doi: 10.1007/s00787-014-0615-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Stephan-Blanchard E, Bach V, Telliez F, Chardon K. Perinatal nicotine/smoking exposure and carotid chemoreceptors during development. Respir Physiolo Neurobiol. 2013;185(1):110–9. doi: 10.1016/j.resp.2012.06.023 [DOI] [PubMed] [Google Scholar]
  • 19.de Vries RBM, Wever KE, Avey MT, Stephens ML, Sena ES, Leenaars M. The Usefulness of Systematic Reviews of Animal Experiments for the Design of Preclinical and Clinical Studies. ILAR Journal. 2014;55(3):427–37. doi: 10.1093/ilar/ilu043 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Arksey H, & O’Malley L. Scoping studies: towards a methodological framework. International journal of social research methodology. 2005;8(1):19–32. [Google Scholar]
  • 21.Leenaars M, Hooijmans CR, van Veggel N, ter Riet G, Leeflang M, Hooft L, et al. A step-by-step guide to systematically identify all relevant animal studies. Laboratory Animals. 2012;46(1):24–31. doi: 10.1258/la.2011.011087 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.de Vries RBM, Hooijmans CR, Tillema A, Leenaars M, Ritskes-Hoitinga M. Updated version of the Embase search filter for animal studies. Laboratory Animals. 2014;48(1):88. doi: 10.1177/0023677213494374 [DOI] [PubMed] [Google Scholar]
  • 23.Covidence. Covidence systematic review software, Veritas Health Innovation. Melbourne, Australia.2019.
  • 24.Li G, Abbade LPF, Nwosu I, Jin Y, Leenus A, Maaz M, et al. A scoping review of comparisons between abstracts and full reports in primary biomedical research. BMC Med Res Methodol. 2017;17(1):1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Avanti Dey

26 Aug 2022

PONE-D-22-05338Developing a taxonomy to describe offspring outcomes in studies involving pregnant mammals’ exposure to non-tobacco nicotine: a systematic scoping reviewPLOS ONE

Dear Dr. Phillips,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. While nearly ready for publication, we request that you address the following-- Please ensure that your PRISMA flowchart details the reasons for record exclusion at each stage, and;- Systematic and scoping reviews should provide an up-to-date overview of the research topic covered. Since the literature search was completed over a year ago, we also request that your update your search to be more current. 

Please submit your revised manuscript by Oct 10 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Avanti Dey, PhD

Staff Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: 

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a useful contribution to the literature surrounding the use of NRT during pregnancy. This scoping review is well laid out and has identified areas where further research could be conducted. I have no suggestions to improve the clarity of this manuscript

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Feb 3;18(2):e0280805. doi: 10.1371/journal.pone.0280805.r002

Author response to Decision Letter 0


6 Oct 2022

We have made the following edits to the manuscript and supporting information as requested. The PRISMA diagram now includes human or non-mammalian participants, conference abstracts or reviews, and exposure to nicotine via lactation as reasons for exclusion. The searches were completed again on 21st September 2022 and any new relevant citations have been added to the final taxonomy figures. The manuscript has been updated to reflect the guidance provided in your email. File names have also been amended to follow these requirements. We have also now added a supporting information file that includes the title, author and publication year for all citations included in the systematic scoping review. The references included in the manuscript have been checked and formatting amended where needed.

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 1

Saeed Ahmed

10 Jan 2023

Developing a taxonomy to describe offspring outcomes in studies involving pregnant mammals’ exposure to non-tobacco nicotine: a systematic scoping review

PONE-D-22-05338R1

Dear Dr. Phillips, 

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Saeed Ahmed, MD

Academic Editor

PLOS ONE

Acceptance letter

Saeed Ahmed

26 Jan 2023

PONE-D-22-05338R1

Developing a taxonomy to describe offspring outcomes in studies involving pregnant mammals’ exposure to non-tobacco nicotine: a systematic scoping review

Dear Dr. Phillips:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Saeed Ahmed

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Search term for database searches.

    Search strategy used to search MEDLINE and Embase.

    (PDF)

    S2 File. Included citations dataset.

    Information for citations included in the systematic scoping review.

    (PDF)

    S3 File. Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist.

    (PDF)

    Attachment

    Submitted filename: Response to reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES